00:00
00:00
00:00

ValiRx plc - Valiseek clinical development update

Thu, 03 Nov 2016, 09:00am GMT

Dr Suzy Dilly and Dr George Morris provide an update after their trip to Tbilisi on the clinical development of ValiRx's novel cancer treatment drug, VAL401. The clinic reported that as the first patient has proceeded sufficiently through the dosing phase of the protocol, the second patient is now approved to also commence dosing and the screening procedure for further enrolment continues to be underway.

Suzanne Dilly
CEO, ValiSeek Limited